The psychedelic medicine market is projected to grow from $3.63 billion in 2024 to over $10 billion by 2032, according to SNS Insider. The FDA has granted Breakthrough Therapy designations to both psilocybin and MDMA-assisted treatments. States are licensing facilitators. And Big Pharma is now making billion-dollar bets on the space: on July 17, 2025, Eli Lilly announced it would acquire AtaiBeckley for $2.8 billion upfront (with milestone payments potentially reaching $3.8 billion), gaining access to a DMT-based therapy in Phase 3 trials for treatment-resistant depression and an MDMA-related pipeline, according to CNBC. Jefferies analysts called psychedelics a drug class that could herald “the biggest change” for psychiatry, according to BioSpace.
But almost nobody is talking about what happens after approval.
Every FDA-approved psychedelic treatment will require physicians, nurses, therapists, treatment rooms, clinical protocols, preparation and integration models, referral networks, insurance credentialing, prior authorizations, pharmacy workflows, patient education, and operational systems that take years to build. Approval does not equal access. It does not create the clinicians, the settings, or the administrative machinery needed to put these medicines into practice.
The future leaders of psychedelic medicine may not simply be the companies developing molecules. They may be the organizations building the platforms capable of delivering them safely, consistently, and at scale.
At Nushama, we have spent years building that infrastructure. More than 21,000 treatment sessions delivered across three markets. Operations in New York City, Rockland County, and Aventura, Florida. A formal Columbia University collaboration focused on training the next generation of psychedelic-informed clinicians. Relationships with more than 800 referring psychiatrists, therapists, primary care physicians, and other partners. We did not wait for the next approval. We built ahead of it.
The demand is here. The delivery system is not.
The pharmacology is arguably the most solved part of the problem. The harder work is delivery: doing it safely, consistently, and for enough people to matter.
The scale of unmet need is staggering. According to the 2024 National Survey on Drug Use and Health (NSDUH), 61.5 million U.S. adults experienced a mental health condition in the past year, and nearly half received no treatment, per data compiled by Innerwell from SAMHSA’s 2024 report. About 35% of people with major depression do not respond to standard antidepressants. That is roughly 2.8 million people looking for something else. The landmark STAR*D study found that remission rates drop from 33% after a first medication to just 13% by the fourth attempt, according to a review in Cognitive FX.
Psychedelic-assisted therapies are positioned to fill that gap. The market reflects it: specialized psychedelic clinics already account for the largest share of end-use revenue in the industry, and the psychedelic therapeutics market is projected to reach $12.4 billion by 2035, with North America holding roughly 52% of that market, according to Precedence Research. Supervised in-clinic pharmacotherapy accounts for about 64% of the therapy model share. The field is growing, and it is growing toward the clinic.
But the infrastructure behind those clinics has not kept pace. The 2024 FDA decision on MDMA-assisted therapy made this painfully visible. On August 9, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Lykos Therapeutics’ MDMA for post-traumatic stress disorder (PTSD) and asked the company to run another phase 3 trial, according to law firm Holland & Knight’s analysis of the decision. Some of the questions were about trial design and data. But a deeper worry ran underneath the review. As one account of the advisory committee’s reasoning put it, panelists “expressed fear that the current infrastructure could not ensure patient safety at scale,” according to an analysis in The Clinical Trial Vanguard.
Read that again. Even reviewers who found the science promising hesitated because the system around the medicine was not ready. The drug was not the sticking point. Everything around it was.
Why traditional psychiatry is not built for this
Traditional psychiatry was designed around 15-minute medication checks, prescription management, and follow-up appointments. It works well for that model. But emerging psychedelic therapies require something fundamentally different.
Many of these treatments involve sessions lasting two to eight hours. They require psychological preparation beforehand. They require integration afterward. They require comfortable, healing-focused environments, not fluorescent-lit exam rooms. They require continuous monitoring, multidisciplinary teams of physicians, nurses, therapists, and integration specialists working together. They require complex reimbursement pathways that most practices have never navigated.
This is not a 15-minute visit. It is a high-touch, high-acuity, long-duration clinical model that most of American healthcare has no infrastructure for. The gap between what these treatments demand and what the existing system can deliver is the central challenge of psychedelic commercialization.
Consider just the clinical side. Psychedelic therapy requires:
- Medical and psychiatric screening to identify who is a good candidate and who is not, reviewing current medications and flagging contraindications before any dose is given.
- The ability to adjust in real time.
- The physical space, the member’s mindset, and the guidance available during the session.
- Preparation and integration: sessions before the journey to build trust and set intentions, sessions afterward to help translate insight into changed behavior.
- Trained people: clinicians, nurses, and integration coaches who understand both the medicine and the vulnerability it creates.
Now add the commercial side: insurance credentialing, prior authorization workflows, pharmacy relationships, billing, data collection, patient outcome tracking, administrative systems. Remove any one of these components and you have a treatment that either cannot reach people or cannot serve them safely.
This is the distinction the field keeps glossing over when it talks about the next approval.
The workforce gap is the hardest problem to solve
The scarcest resource in psychedelic medicine is not the compound. It is people who know how to hold the experience. And the gap between supply and demand is widening fast.
Psychedelic-assisted therapy is unusually labor-intensive. A full treatment protocol in current clinical trials can require more than 42 hours of therapist involvement per person, often delivered by a two-clinician team, according to Prohibition Partners’ Psychedelics as Medicine report. That model does not scale by adding more vials. It scales only by training more skilled clinicians, which takes years.
The numbers are sobering. The U.S. currently has a few hundred licensed psilocybin facilitators. If psilocybin receives FDA approval (projected around 2027-2028), the number of trained practitioners needed would run into the tens of thousands, according to HealingMaps’ analysis of the workforce gap. Oregon has roughly 300 licensed facilitators; Colorado certified its first 51 in 2024. Training programs take 6 to 18 months and cost $3,000 to $15,000 per person. The pipeline is producing hundreds when the field will need tens of thousands.
Meanwhile, the wider mental health workforce is already stretched thin. About 40% of the U.S. population lives in a provider shortage area, according to the Health Resources and Services Administration (HRSA). Researchers writing in Frontiers in Psychiatry in 2023 noted that, according to the Substance Abuse and Mental Health Services Administration, the field faced a projected shortage of 31,000 mental health practitioners. New psychedelic therapies will arrive into a system that is already short-staffed. Approval alone will not create the clinicians needed to deliver these treatments responsibly.
This is why Nushama has invested in training as a core function, not an afterthought. Our formal collaboration with Columbia University is focused on training the next generation of psychedelic-informed clinicians. Our team is led by Dr. Steven Radowitz, our Chief Medical Officer, and includes physicians, nurses, and integration coaches who have been delivering ketamine-assisted therapy for years, not months. That institutional knowledge, built session by session over more than 21,000 treatments, cannot be assembled overnight. You can read more about what makes our approach different.
Ketamine clinics as the training ground for psychedelic commercialization
Ketamine is not equivalent to future psychedelic therapies. But running a modern ketamine clinic has become one of the best real-world training grounds for operationalizing treatments that share a similar delivery profile.
Think about what a high-functioning ketamine program teaches an organization: how to manage longer treatment workflows, how to build preparation and integration models, how to coordinate multidisciplinary teams, how to create hospitality-driven care environments, how to handle higher-acuity psychiatric care, how to educate members, and how to manage the logistics of treatments that take hours rather than minutes.
Many future psychedelic therapies will require these same capabilities. The organizations that have already built them will have a substantial head start.
At Nushama, we administer ketamine through an intravenous (IV) line rather than as a lozenge or at-home spray, and the reason is control. With an IV, a clinician can adjust the infusion rate in real time or stop the session within minutes if a member feels uncomfortable, blood pressure rises, or dissociation (a temporary altered state in which a person may feel detached from their body or surroundings) becomes too intense. At-home and intranasal options remove that control. Once a lozenge is swallowed, absorption continues regardless of how the person responds, with no clinician on hand to intervene.
This is not a theoretical preference. It is an operational decision rooted in more than 21,000 treatment sessions. We built one of the largest IV ketamine programs in New York City before expanding into Spravato (esketamine), medication management, and ketamine for alcohol use disorder (KARE). Each modality added new layers of operational complexity: REMS compliance for Spravato, insurance credentialing with major commercial and government payers, prior authorization workflows, pharmacy relationships. These capabilities are often invisible, but they become the difference between a clinic that can deliver a new treatment and one that cannot. For a closer look at the trade-offs between delivery methods, see our comparison of IV and intramuscular ketamine.
The patient experience is an operational decision
The medicine is a catalyst, not a cure. What a member does in the days around the journey often matters as much as the dose. And the environment in which they receive the medicine is not an aesthetic choice. It is an operational one that affects clinical outcomes.
Unlike traditional healthcare environments, Nushama intentionally designed its clinics around the therapeutic experience. Private treatment rooms. Eye masks. Curated music. Comfortable spaces that feel more like a healing retreat than a hospital. These are not luxuries. They are part of set and setting, the conditions that shape how a psychedelic experience unfolds, and they require deliberate planning, investment, and operational protocols to maintain consistently across multiple locations.
Our protocol runs in three phases. In preparation, a member meets with a licensed clinician or integration coach to build a therapeutic alliance, discuss their history, and set intentions. During the journey, a guide is present at the start and end of the session, and the environment supports the internal work. In integration, the member works to carry insight into daily life while the brain’s window for change is still open.
Skip the integration step and you let that window close without support. That is the difference between a memorable afternoon and a lasting shift. We have written more about why integration does so much of the heavy lifting.
Future psychedelic delivery models will face the same operational questions: How do you design a space that supports healing? How do you standardize preparation and integration across sites? How do you train staff to deliver hospitality-driven care that also meets clinical safety standards? These are questions Nushama has been answering operationally for years.
Research and evidence generation
The case for full-container care is not only philosophical. A 2025 real-world study, “Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm” by Henry A. MacConnel, Mitch Earleywine, and Steven Radowitz, reported meaningful and durable symptom reduction for people living with treatment-resistant PTSD when IV ketamine was delivered inside a structured psychedelic paradigm rather than as a standalone infusion.
The detail worth sitting with is the phrase “psychedelic paradigm.” The reductions were observed not simply because ketamine was given, but because it was given within a supportive container of preparation, setting, and integration. The infrastructure is not a nice-to-have around the medicine. It may be part of why the medicine works. You can read more about how ketamine may support people with PTSD and trauma.
This study is one of the largest PTSD IV ketamine studies of its kind, and it reflects a commitment to evidence generation rather than simply clinical delivery. The collaboration with Columbia University extends this work into academic credibility, contributing to the body of knowledge that regulators, payers, and referring clinicians rely on when evaluating new treatments. Data collection, patient outcome tracking, and standardized clinical SOPs across sites are not glamorous, but they are the infrastructure that turns clinical experience into publishable evidence.
Access and patient acquisition are infrastructure too
Even excellent care does little good if the people who need it most cannot find it or reach it. Cost, stigma, and simple lack of awareness keep many people away from treatments that might help them.
Future psychedelic medicines will still require patients to find providers. Commercial infrastructure matters just as much as clinical infrastructure. Nushama has invested in building demand generation alongside clinical capacity: SEO and GEO (generative engine optimization) for AI-driven search, paid digital marketing, community events, PR, organic social media, and structured referral pathways from the more than 800 psychiatrists, therapists, primary care physicians, and other partners in our referral network. These networks cannot be created overnight once a drug receives approval.
Nushama has also been featured by The New York Times, The Wall Street Journal, Forbes, Good Morning America, and The Times, reflecting growing public and institutional recognition of this model of care.
Community programming, scholarship support for those who face financial barriers, and clear, plain-language guidance on what to expect all lower the threshold to care. Treating access as an afterthought quietly undoes the rest of the work.
The next chapter belongs to the organizations that built the platform
The next few years will bring more approvals, more compounds, and more capital. Phase III pipelines are expanding. Payer adoption is growing. Wall Street is paying closer attention. The conversation has evolved past whether psychedelic-assisted therapies work and toward how to deliver them responsibly.
But growth without infrastructure creates its own risks. More demand chasing too few trained clinicians, too few supervised settings, and too few integrated care models means more people will encounter psychedelic medicine without the safety container that makes it work. The FDA’s hesitation on MDMA was a preview of what happens when the science runs ahead of the system built to deliver it.
Nushama exists because we saw this gap years ago. While much of the field focused on which molecule would win approval first, we focused on building the clinical platform: physician-led medical oversight, IV delivery for real-time dosing control, structured preparation and integration, standardized workflows and safety procedures across multiple sites, REMS compliance, insurance credentialing with major commercial and government payers, and a team trained in both the medicine and the vulnerability it creates.
The result is an organization that has already built much of the infrastructure the next generation of mental health treatments will require: preparation protocols, integration models, multidisciplinary care teams, clinical SOPs, data collection and outcome tracking, multi-site operations, regulatory compliance, and patient acquisition systems.
When the next compound clears the FDA, the question will not be whether it works in a trial. It will be whether anyone can screen the right candidates, dose them safely, guide them through the experience, support the integration that makes change durable, navigate the reimbursement, and do all of that consistently across multiple locations.
The future of psychedelic medicine will not be determined solely by scientific breakthroughs. It will also be shaped by the organizations capable of translating those breakthroughs into scalable, safe, evidence-based patient care.
We chose to build that platform first. For a fuller picture of how a journey unfolds from consult to integration, see our complete guide to psychedelic therapy or our overview of our practices for safe psychedelic care.
FAQs
What is the biggest barrier to scaling psychedelic therapy?
The main barrier is not the availability of the medicines but the clinical infrastructure needed to deliver them safely. That includes trained clinicians, medical screening, supervised dosing, and structured preparation and integration. The U.S. currently has only a few hundred licensed psilocybin facilitators, but would need tens of thousands if psilocybin receives FDA approval. The mental health workforce is already short-staffed, with 40% of the U.S. population living in a provider shortage area. Training enough skilled psychedelic practitioners is likely the hardest constraint to solve.
Why does Nushama use IV ketamine instead of at-home options?
An intravenous line gives clinicians real-time control. They can adjust the dose or stop a session within minutes if a member becomes uncomfortable or their vital signs change. At-home lozenges and sprays remove that ability, since absorption continues regardless of how the person responds and no clinician is present to intervene. For a controlled substance that alters consciousness, medical supervision supports both safety and results.
What are preparation and integration in ketamine therapy?
Preparation is the work done before a session, where a member meets with a clinician or integration coach to build trust, review their history, and set intentions. Integration is the work afterward, translating the insights from the experience into lasting changes in daily life. Both surround the medicine itself and are considered essential to durable results rather than optional extras.
Does the setting really affect how ketamine therapy works?
Emerging evidence suggests it can. A 2025 real-world study on IV ketamine for treatment-resistant PTSD reported meaningful, sustained symptom reduction when the medicine was delivered within a structured psychedelic paradigm that included preparation, a supportive setting, and integration, rather than as a standalone infusion. The environment and support around the dose appear to be part of why the treatment helps.
Is psychedelic-assisted therapy medically supervised at Nushama?
Yes. Every member begins with a full medical and psychiatric intake to confirm the treatment is appropriate and to review any contraindications. Dosing is handled by licensed physicians, sessions are monitored by clinical staff, and preparation and integration support is provided throughout. This medically supervised model is central to how care is delivered.
Curious whether this approach is right for you or someone you love? Speak with our care team to talk through your history, your questions, and what a supported path might look like.
